X4 Pharmaceuticals (NASDAQ:XFOR) Posts Earnings Results, Beats Estimates By $0.02 EPS

X4 Pharmaceuticals (NASDAQ:XFOR) posted its quarterly earnings data on Wednesday. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02, Zacks reports. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%. The business had revenue of $2.88 million during the quarter, compared to analysts’ expectations of $2.30 million.

X4 Pharmaceuticals Stock Performance

XFOR opened at $3.24 on Thursday. The stock’s 50 day simple moving average is $3.28 and its 200-day simple moving average is $3.79. The company has a current ratio of 11.30, a quick ratio of 11.02 and a debt-to-equity ratio of 0.49. The stock has a market cap of $321.24 million, a PE ratio of -2.70 and a beta of 0.47. X4 Pharmaceuticals has a 1 year low of $2.43 and a 1 year high of $4.83.

Insider Buying and Selling

In other news, CFO David Kirske sold 11,767 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $2.86, for a total value of $33,653.62. Following the completion of the transaction, the chief financial officer owned 155,983 shares in the company, valued at approximately $446,111.38. This represents a 7.01% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Adam R. Craig sold 47,436 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total transaction of $210,615.84. Following the completion of the transaction, the chairman owned 328,651 shares of the company’s stock, valued at approximately $1,459,210.44. This represents a 12.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 83,779 shares of company stock valued at $353,387 over the last ninety days. 1.13% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on XFOR. Wells Fargo & Company started coverage on X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 target price on the stock. Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $11.25.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.